Hypoxia regulates TRAIL sensitivity of colorectal cancer cells through mitochondrial autophagy by Ehrenschwender, Martin et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
Hypoxia regulates TRAIL sensitivity of colorectal cancer cells 
through mitochondrial autophagy
Gertrud Knoll1, Sebastian Bittner1, Maria Kurz1, Jonathan Jantsch1, Martin 
Ehrenschwender1
1Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany
Correspondence to: Martin Ehrenschwender, e-mail: martin.ehrenschwender@ukr.de
Keywords: TRAIL, SMAC mimetic, death receptor, hypoxia
Received: December 22, 2015    Accepted: April 24, 2016    Published: May 6, 2016
ABSTRACT
The capacity of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) 
to selectively induce cell death in malignant cells triggered numerous attempts for 
therapeutic exploitation. In clinical trials, however, TRAIL did not live up to the 
expectations, as tumors exhibit high rates of TRAIL resistance in vivo. Response 
to anti-cancer therapy is determined not only by cancer cell intrinsic factors (e.g. 
oncogenic mutations), but also modulated by extrinsic factors such as the hypoxic 
tumor microenvironment.
Here, we address the effect of hypoxia on pro-apoptotic TRAIL signaling 
in colorectal cancer cells. We show that oxygen levels modulate susceptibility to 
TRAIL-induced cell death, which is severely impaired under hypoxia (0.5% O2). 
Mechanistically, this is attributable to hypoxia-induced mitochondrial autophagy. 
Loss of mitochondria under hypoxia restricts the availability of mitochondria-derived 
pro-apoptotic molecules such as second mitochondria-derived activator of caspase 
(SMAC), thereby disrupting amplification of the apoptotic signal emanating from the 
TRAIL death receptors and efficiently blocking cell death in type-II cells. Moreover, 
we identify strategies to overcome TRAIL resistance in low oxygen environments. 
Counteracting hypoxia-induced loss of endogenous SMAC by exogenous substitution of 
SMAC mimetics fully restores TRAIL sensitivity in colorectal cancer cells. Alternatively, 
enforcing a mitochondria-independent type-I mode of cell death by targeting the 
type-II phenotype gatekeeper X-linked inhibitor of apoptosis protein (XIAP) is equally 
effective.
Together, our results indicate that tumor hypoxia impairs TRAIL efficacy but 
this limitation can be overcome by combining TRAIL with SMAC mimetics or XIAP-
targeting drugs. Our findings may help to exploit the potential of TRAIL in cancer 
therapy.
INTRODUCTION
Among the tumor necrosis factor (TNF) ligands, 
TNF-related apoptosis-inducing ligand (TRAIL) is 
unique due to its capacity to selectively induce cell 
death in tumor cells [1]. TRAIL binding to TRAIL 
receptor 1 (TRAIL-R1) or TRAIL-R2 triggers assembly 
of a death-inducing signaling complex (DISC). This 
platform allows stepwise caspase-8 activation and 
initiates a cascade of proteolytic cleavage events that 
culminate in caspase-3 activation, finally triggering the 
execution phase of apoptosis. In so-called type-I cells, 
caspase-8-mediated cleavage of caspase-3 is followed 
by robust autocatalytic caspase-3 processing and 
efficient cell death induction. In type-II cells, however, 
X-linked inhibitor of apoptosis protein (XIAP) stalls 
caspase-3 maturation an intermediate step and has to 
be overridden by a mitochondria-derived amplification 
of the death signal. In this scenario, caspase-8 cleavage 
of the BH3-interacting domain death agonist (Bid) to 
tBid [2] activates Bcl2-associated X protein (Bax) and 
Bcl2-antagonist/killer (Bak). Bax and Bak form a pore 
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complex in the outer mitochondrial membrane and 
unleash pro-apoptotic factors such as cytochrome c, 
HtrA2 and second mitochondria-derived activator of 
caspase (SMAC) [3]. Together with apoptotic-protease-
activating factor 1 (Apaf-1), cytochrome c forms the 
‘apoptosome’, a molecular scaffold for caspase-9 
activation, which in turn boosts downstream effector 
caspase activation. SMAC and HtrA2 act synergistically 
by neutralizing cytosolic inhibitors of apoptosis proteins 
(IAPs), especially XIAP [4, 5].
Soon after its discovery, TRAIL emerged as a 
promising anti-cancer agent with encouraging results 
in pre-clinical studies. Disappointingly, the therapeutic 
benefit of TRAIL in clinical trials is to date rather 
limited [6]. The reasons for TRAIL’s sobering clinical 
performance are incompletely understood. We and 
others previously showed that cancer-cell intrinsic 
factors, such as the oncogenic PIK3CA H1047R 
mutation conferred high-level TRAIL resistance in 
colorectal cancer cells [7, 8]. Additionally, extrinsic 
factors, such as the tumor microenvironment affect 
the response to anti-cancer therapies [9]. In solid 
malignancies, fast proliferation can outgrow the 
supply of nutrients and oxygen provided by the 
malformed tumor vasculature. Hypoxia is common in 
human cancers and grants stabilization of hypoxia-
inducible factor 1α (HIF1α). This transcription factor 
ensures cell survival through adaptive changes in cell 
metabolism (reviewed in [10]). Notably, HIF1α has also 
been implicated in carcinogenesis and metastasis of 
colorectal cancer [11] and overexpression is associated 
with poor prognosis [12].
Here, we show that hypoxia induced TRAIL 
resistance in colorectal cancer cells. Oxygen 
deprivation reduced the levels of mitochondria-derived 
pro-apoptotic SMAC and HtrA2 molecules by hypoxia-
induced mitophagy, thereby disrupting mitochondria-
dependent amplification of the TRAIL-triggered death 
signal and blocking apoptosis in type-II cells. Inhibition 
of hypoxia-induced mitophagy or replacement of 
endogenous SMAC with exogenously added SMAC 
mimetics fully restored TRAIL cytotoxicity under 
hypoxic conditions. Additionally, switching type-
II cells to a type-I mode of cell death by targeting 
the type-II phenotype gatekeeper XIAP rendered 
mitochondrial death signal amplification dispensable 
and allowed full-blown TRAIL-induced apoptosis under 
hypoxic conditions. Together, we identified hypoxia 
as an extrinsic modulator of TRAIL susceptibility in 
colorectal cancer cells. Therapeutically, our results 
indicate that combinatorial treatments with TRAIL and 
SMAC mimetics or XIAP-targeting drugs can overcome 
hypoxia-induced TRAIL resistance and may offer a 
promising strategy to exploit the potential of TRAIL in 
cancer therapy.
RESULTS
Hypoxia reduces TRAIL-induced cell death in 
colorectal cancer cells
Hypoxia (0.5% O2) significantly attenuated TRAIL-
induced cell death in the colorectal cancer cell lines 
HCT116 (Figure 1A), HCT-8 (Figure 1C) and DLD1 
(Figure 1D) compared to normoxia (ambient air, ~21% 
O2) in MTT- (Figure 1A, 1C, 1D) and crystal violet-based 
viability assays (Figure 1B). Expectedly, TRAIL-induced 
loss of viability under normoxic conditions was associated 
with activation of caspase-3, a prototypic effector caspase 
in apoptosis (Figure 1E). TRAIL-triggered translocation of 
phosphatidylserine (PS) to the outer leaflet of the plasma 
membrane, another hallmark of ongoing apoptosis, was 
prominent under normoxia but tremendously reduced 
under hypoxia (Figure 1F). We next investigated whether 
hypoxia selectively impairs TRAIL death receptor-mediated 
cytotoxic effects or also influences pro-apoptotic signaling 
of other death receptors such as CD95. Indeed, hypoxia 
attenuated cell death in CD95L-treated HCT-8 (Figure 1G) 
and HCT116 cells (Figure 1H), thereby pointing to a more 
general role of oxygen levels in modulating death receptor-
associated pro-apoptotic signaling pathways. Hypoxia-
mediated TRAIL resistance was dependent on the persistent 
absence of oxygen and rapidly vanished when normoxic 
conditions were restored (Figure 1I). The attenuation of 
TRAIL-induced cell death visible in DLD1 cells under 
hypoxic conditions (black bars) was completely reversible 
by normoxic cultivation for additional 24 h (grey bars) or 
48 h (green bars) before adding TRAIL. Additionally, the 
extent of hypoxia-induced TRAIL resistance correlated with 
the levels of available oxygen (Figure 1J). Whereas TRAIL-
induced cell death was strongly inhibited in the presence 
of 0.5% O2 (black bars) and 5% O2 (grey bars), oxygen 
levels of 7.5% (red bars) and above fully restored TRAIL 
cytotoxicity to normoxic levels (white bars). Notably, 
oxygen levels between 5 and 10% are physiologically 
encountered in various tissues [13]. Together, these date 
demonstrated that oxygen levels modulate death receptor-
induced cell death in colorectal cancer cells.
Hypoxia alters expression of pro- and  
anti-apoptotic proteins
We next addressed the molecular mechanisms 
underlying hypoxia-induced TRAIL resistance in 
colorectal cancer cells. Using an antibody-based protein 
array (Figure 2A), we measured oxygen-dependent 
changes in the abundance of pro- and anti-apoptotic 
proteins in cell lysates. Hypoxia not only reduced 
expression levels of TRAIL-R1, TRAIL-R2 and Fas-
associated death domain (FADD), but also lowered the 
abundance of mitochondria-derived pro-apoptotic factors 
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Figure 1: Hypoxia reduces TRAIL-induced cell death in colorectal cancer cells. A–D. HCT116, HCT-8 and DLD1 cells 
were grown under normoxic (21% O2) or hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells were challenged with the indicated 
concentrations of TRAIL for another 18 h. Viability was measured using MTT (A, C, D) or crystal violet (B) staining. Values are means ± 
SEM from three experiments. E. DLD1 cells were challenged with the indicated concentrations of TRAIL for 5 h. Caspase-3 activity was 
measured using the fluorogenic substrate (DEVD)2-R110. One representative experiment of three performed is shown. AU, arbitrary units. F. 
DLD1, HCT-8 and HCT116 cells were grown under normoxic (21% O2) or hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells were 
challenged with 256 ng/mL TRAIL for 3 h or left untreated. Translocation of phosphatidylserine to the outer leaflet of the plasma membrane 
was measured using a fluorogenic Annexin V derivate. One representative experiment of two performed is shown. PS, phosphatidylserine. 
G, H. HCT-8 and HCT116 cells were grown under normoxic (21% O2) or hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells were 
challenged with the indicated concentrations of CD95L for additional 18 h. Cell viability was measured using MTT staining. Values are 
means ± SEM from three experiments. I. DLD1 cells were grown under normoxic (21% O2) or hypoxic (0.5% O2) conditions for 18 h. 
Hypoxia-experienced cells were subsequently split in three groups and grown in an environment containing 0.5% O2 (black bars) for 24 
h or 21% O2 for 24 h (grey bars) or 48 h (green bars). Subsequently, cells were challenged with the indicated concentrations of TRAIL 
for 18 h. Cell viability was measured using MTT staining. Values are means ± SEM from three experiments. J. DLD1 cells were grown 
under normoxic (21% O2) or various hypoxic (0.5% - 10% O2) conditions for 18 h. Subsequently, cells were challenged with the indicated 
concentrations of TRAIL for another 18 h. Viability was measured using MTT staining. Values are means ± SEM from three experiments.
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such as HtrA2 and SMAC. Expression of caspase-3, an 
essential molecule in the effector phase of apoptosis, 
did not significantly differ in hypoxic and normoxic 
conditions (Figure 2A). Therefore, hypoxia most likely 
blocked activation of the effector phase of apoptosis 
rather than abolishing the effector mechanism itself. 
Oxygen deprivation also reduced the levels of the anti-
apoptotic proteins Survivin and XIAP, whereas the levels 
of Bcl-2, Bcl-XL, cIAP1 and cIAP2 were only minimally 
affected. Apparently, this reduction was not sufficient to 
enhance TRAIL sensitivity, as hypoxia decreased rather 
than increased TRAIL-induced cytotoxicity in colorectal 
cancer cells (Figure 1). To validate our proteome array 
data, we examined whether the hypoxia-induced loss 
of pro-apoptotic proteins functionally contributes to the 
attenuated TRAIL sensitivity observed in a low oxygen 
environment. Importantly, a mere reduction of a pro-
apoptotic molecule in cell lysates not necessarily promotes 
Figure 2: Hypoxia changes the expression levels of pro- and anti-apoptotic proteins but does not impair TRAIL-induced 
DISC formation. A. DLD1 cells were grown under normoxic (21% O2) or hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells 
were lysed and relative expression levels of the indicated proteins were measured using an antibody-based array (see Material and Methods 
section). Proteins were quantified using densitometry and normalized to reference spots. Data shown are representative of two experiments 
performed. AU, arbitrary units. B. DLD-1, HCT-8 and HCT116 cells were grown for 18 h under normoxic (21% O2) or hypoxic (0.5% O2) 
conditions and subsequently analyzed for TRAIL-R1, TRAIL-R2, TRAIL-R3 and TRAIL-R4 cell surface expression using flow cytometry. 
Data shown are representative of three experiments performed. C. TRAIL-R1/-R2 signaling complexes were induced in DLD1 cells grown 
for 18 h under normoxic (21% O2) or hypoxic (0.5% O2) conditions by stimulation with Fc-FLAG-scTRAIL (1 μg/mL) for 90 min. Proteins 
associated with Fc-FLAG-scTRAIL were immunoprecipitated using protein G agarose and were analyzed together with the corresponding 
lysates by Western blotting for the presence of TRAIL-R1 and TRAIL-R2 and the DISC components FADD, FLIP and caspase-8. Data 
shown are representative of two experiments performed. D. DLD1 cells were grown for 18 h under normoxic (21% O2) or hypoxic (0.5% 
O2) conditions and subsequently challenged with 256 ng/mL TRAIL for the indicated periods of time. Caspase-8 activity was measured 
using the fluorogenic substrate (Ac-IETD)2-R110. Values are means ± SEM from three experiments. AU, arbitrary units.
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survival, as factor-specific thresholds and the subcellular 
location of proteins have to be considered. For example, 
the observed decrease in the total cellular amount of 
TRAIL-R1 and TRAIL-R2 under hypoxia allows no 
conclusion regarding the cell surface expression of the 
TRAIL death receptors. Ligand binding to death receptors 
occurs at the plasma membrane and initiates the apoptosis-
inducing signaling cascade, cell surface localization 
is therefore functionally of outstanding importance 
(for review see [14]). Flow cytometry revealed that the 
observed reduction in the total amount of TRAIL-R1 and 
TRAIL-R2 under hypoxic conditions did not correlate 
with decreased expression of these death receptors at 
the cell surface (Figure 2B). TRAIL-R1 and TRAIL-R2 
surface expression under hypoxia was comparable to 
normoxia. Additionally, lowering oxygen levels to 0.5% 
did not affect expression levels of the decoy receptors 
TRAIL-R3 and TRAIL-R4. In line with these findings, 
immunoprecipitation experiments demonstrated that 
TRAIL-induced receptor signaling complex formation 
occurred equally effective under hypoxic or normoxic 
conditions (Figure 2C). Notably, we did not detect 
significant oxygen-dependent differences in the amount 
of precipitated TRAIL-R1 and TRAIL-R2. Although total 
cellular FADD levels were reduced under hypoxia (Figure 
2A), FADD was precipitated together with TRAIL-R1 and 
TRAIL-R2 (Figure 2C), suggesting that the remaining 
amount was still sufficient to form a functional death 
receptor-associated signaling complex. In line with this, 
TRAIL-induced processing of the caspase-8 p55/53 
pro-form via the p43/41 intermediate at the DISC to the 
enzymatically active p18 fragment occurred roughly to 
the same extend under hypoxic or normoxic conditions 
(Figure 2C). Undisturbed TRAIL-induced caspase-8 
activation under oxygen deprivation was also confirmed 
in caspase-8 activity assays (Figure 2D). Together, our 
data indicated that the initial steps of apoptosis induction 
were intact and hypoxia blocked TRAIL-induced cell 
death downstream of receptor-ligation, DISC formation 
and caspase-8 activation.
Hypoxia induces loss of mitochondrial mass
Following activation of initiator caspases at the 
DISC, release of mitochondria-derived apoptosis-
promoting proteins such as HtrA2 and SMAC are in 
type-II cells essential (and in type-I cells accelerative) 
for full-blown effector caspase activation and cell 
death. The reduced HtrA2 and SMAC levels under 
low oxygen conditions (Figure 2A) could therefore 
impair TRAIL-induced cell death downstream of DISC 
formation. Efficient release of apoptotic proteins from 
the intermembrane space of mitochondria depends on 
a stimulus-triggered increase in cytosolic Ca2+ [15]. In 
CD95 signaling, CD95L-induced Ca2+ efflux from the 
endoplasmic reticulum is important for mitochondrial 
permeabilization and CD95-mediated apoptosis [16, 
17]. We analyzed TRAIL-induced changes in cytosolic 
Ca2+ under hypoxic and normoxic conditions (Figure 
3A). In both scenarios, TRAIL was comparably effective 
in augmenting cytosolic Ca2+, suggesting that oxygen-
dependent differences in Ca2+ fluxes are unlikely to explain 
the lower levels of mitochondria-derived pro-apoptotic 
molecules under hypoxia.
Notably, a previous study demonstrated that 
hypoxia triggered mitochondrial autophagy as an adaptive 
metabolic response [18]. Staining of mitochondria in 
DLD1 cells grown under hypoxic conditions using 
the membrane potential-independent MitoTracker 
dye revealed a reduced staining intensity compared to 
normoxic controls (Figure 3B). This pointed to a hypoxia-
induced decrease of mitochondrial mass. Importantly, 
cell proliferation was comparable under normoxic 
and hypoxic conditions (Figure 3C), excluding simple 
differences in cell number as causative for the decrease 
in mitochondrial mass under low oxygen. Additionally, 
enhanced autophagosome formation was detectable 
under hypoxic conditions (Figure 3D). In line with 
hypoxia-induced mitophagy, pharmacological blockade 
of autophagy using 3-methyladenine (3MA) attenuated 
the loss of mitochondria (Figure 3E). Moreover, 3MA 
overcame TRAIL resistance in hypoxic DLD1, HCT-8 
and HCT116 cells (Figure 3F), thereby demonstrating the 
functional relevance of mitophagy for hypoxia-induced 
TRAIL resistance. In the absence of oxygen, HIF1α 
ensures (tumor) cell survival by coordinating the broad 
metabolic reprogramming at the transcriptional level 
(reviewed in [10]). DLD1 cells grown under hypoxic 
conditions expectedly stabilized HIF1α (Figure 3G). 
Interestingly, a recent study demonstrated a crucial role for 
HIF1α in hypoxia-induced mitophagy [18]. Consequently, 
inhibiting HIF1α in our experimental system should 
decrease hypoxia-induced mitophagy and enhance 
TRAIL-induced cell death. Indeed, blocking HIF1α using 
the pharmacological inhibitor Bay87-2243 [19] (Figure 
3G) attenuated or even abolished oxygen-dependent 
differences in TRAIL sensitivity (Figures 3H and 3I). In 
sum, we demonstrated that oxygen deprivation reduced 
TRAIL sensitivity of colorectal cancer cells via hypoxia-
induced mitophagy.
SMAC mimetics overcome hypoxia-induced 
TRAIL resistance
The observed loss of mitochondria-derived pro-
apoptotic proteins (such as SMAC) under hypoxic conditions 
(Figure 2A) was accompanied by a decrease in mitochondrial 
mass (Figure 3B) and impaired TRAIL sensitivity, 
suggesting that the release of apoptosis-promoting factors 
from mitochondria is essential for efficient propagation of 
the apoptotic signal. In line with this, HCT116 cells deficient 
for Bax (HCT116 Bax-/-), a crucial player in mitochondrial 
permeabilization during apoptosis, exhibited high-level 
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TRAIL resistance irrespective of the surrounding oxygen 
levels (Figure 4A). Consequently, restoring or imitating 
the mitochondria-mediated amplification of the apoptotic 
signal, e.g. with small-molecules mimicking the endogenous 
IAP antagonist SMAC (SMAC mimetics), could allow 
effective TRAIL-based treatments even in hypoxic tumor 
microenvironments. The SMAC mimetic BV6 efficiently 
reduced cellular levels of XIAP (Figure 4B) and re-
sensitized HCT116 Bax-/- (Figure 4A), HCT116, HCT-8 and 
DLD1 cells grown under hypoxic conditions to TRAIL- 
and/or CD95L-induced cell death (Figure 4C and 4E-4H). 
Notably, enhanced cytotoxicity of TRAIL in the presence 
Figure 3: Hypoxia-induced mitochondrial autophagy decreases TRAIL sensitivity. A. DLD1 cells were grown under 
normoxic (21% O2, white bars) and hypoxic (0.5% O2, black bars) conditions for 18 h and subsequently challenged with 256 ng/mL 
TRAIL for the indicated periods of time. Cytosolic Ca2+ levels were measured using Fluo-4 staining and quantified in a microplate reader. 
To calculate TRAIL-induced Ca2+ influx (Δ RFU), the fluorescence intensity from untreated controls was subtracted from every condition. 
Values are means ± SEM from three experiments. RFU, relative fluorescent units. B. DLD1 cells were grown as in (A) followed by staining 
of mitochondria using MitoTracker Green FM. Fluorescence intensity was quantified using a microplate reader and is given relative to 
the normoxic control. Values are means ± SEM from three experiments. C. DLD1 cells were grown as in (A) and cell proliferation was 
measured using MTT staining. Values are means ± SEM from three experiments. D. Cells were treated as in (A) followed by autophagosome 
staining. Fluorescence intensity was quantified using a microplate reader and is given relative to the normoxic control. Values are means ± 
SEM from three experiments. E. DLD1 cells were grown as in (A) in the presence of the autophagy inhibitor 3MA (12 mM). Subsequently, 
mitochondria were stained using MitoTracker and fluorescence was quantified in a microplate reader. Data are given relative to the 
corresponding normoxic controls. Values are means ± SEM from three experiments. F. DLD1, HCT-8 and HCT116 cells were grown as 
in (A) in the presence and absence of the autophagy inhibitor 3MA (12 mM) and subsequently challenged with the TRAIL (256 ng/mL) 
for 18 h. Viability was measured using MTT staining. Values are means ± SEM from three experiments. G. DLD1 cells were grown for 18 
h under normoxic (21% O2) and hypoxic (0.5% O2) conditions in the presence and absence of the HIF1α inhibitor Bay87-2243 (50 μM). 
HIF1α levels were analyzed by Western blotting, tubulin served as loading control. H, I. DLD1 and HCT-8 cells were grown as in (A) in 
the presence and absence of the HIF1α inhibitor Bay87-2243 (25 μM) and subsequently challenged with the indicated concentrations of 
TRAIL for 18 h. Viability was measured using MTT staining. Values are means ± SEM from three experiments.
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Figure 4: SMAC-mimetics overcome hypoxia-induced apoptosis resistance. A. left panel: HCT116 Bax-/- cells were grown 
under normoxic (21% O2) and hypoxic (0.5% O2) conditions for 18 h in the presence and absence of BV6 (6.25 μM). Subsequently, cells 
were challenged with the indicated concentrations of TRAIL for another 18 h. Viability was measured using MTT staining. Values are 
means ± SEM from three experiments. Right panel: Bax expression in HCT116 wildtype and HCT116 Bax-/- cells was assessed by Western 
blotting. Tubulin served as loading control. B. HCT116, HCT-8 and DLD1 cells were grown as in (A) in the presence and absence of the 
SMAC mimetic BV6 (HCT116: 6.25 μM; HCT8: 6.25 μM; DLD1: 25 μM). XIAP levels were analyzed by Western blotting, tubulin served 
as loading control. C–H. HCT116, HCT-8 and DLD1 cells were grown as in (A) in the presence and absence of the SMAC mimetics 
BV6 (HCT116: 6.25 μM; HCT8: 6.25 μM; DLD1: 25 μM) or LCL161 (25 μM). Thereafter, cells were stimulated with the indicated 
concentrations of TRAIL or CD95L for 18 h and cell viability was measured using MTT staining. Values are means ± SEM from three 
experiments. I. DLD1 cells were grown under hypoxic conditions (0.5% O2) for 18 h in the presence of BV6 (25 μM, black bars) or BV6 
+ zVAD-fmk (100 μM, white bars). Subsequently, cells were treated with the indicated concentrations of TRAIL for 18 h. Cell viability 
was measured using MTT staining. Values are means ± SEM from three experiments. J. DLD1 and HCT-8 cells were grown under hypoxic 
(0.5% O2) conditions for 18 h in the presence and absence of BV6 (DLD1: 25 μM; HCT-8: 6.25 μM). Subsequently, cells were challenged 
with the indicated concentrations of TRAIL for 3 h. Translocation of phosphatidylserine to the outer leaflet of the plasma membrane was 
measured using a fluorogenic Annexin V derivate. One representative experiment of two performed is shown. PS, phosphatidylserine.
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of SMAC mimetics was not attributable to BV6-induced 
autocrine TNF secretion, as TNF was not detectable in the 
supernatant of BV6-treated cells (data not shown). LCL161, 
a SMAC mimetic that already entered phase II clinical trials 
(reviewed in [20]), also increased TRAIL-induced cell death 
under low oxygen levels (Figure 4D). The pan-caspase 
inhibitor zVAD-fmk completely abrogated TRAIL-induced 
cell death in BV6-treated DLD1 cells under hypoxia (Figure 
4I) and combinatorial treatment with BV6 and TRAIL 
strongly increased PS exposure at the outer leaflet of the 
plasma membrane (Figure 4J), together pointing to ongoing 
apoptotic rather than necroptotic cell death. Collectively, our 
data highlighted that SMAC mimetics efficiently overcame 
hypoxia-induced TRAIL resistance in colorectal cancer 
cells.
XIAP is critical for hypoxia-induced TRAIL 
resistance
Apparently, hypoxia-induced mitophagy disrupted 
the required mitochondrial amplification of pro-apoptotic 
TRAIL signaling, thereby effectively blocking apoptosis 
in type-II cells. The anti-apoptotic protein XIAP acts 
as a gatekeeper of the type-II phenotype [21, 22]. We 
and others demonstrated that targeting XIAP is capable 
to convert type-II to type-I cells [21, 23, 24]. Our data 
indicated intact TRAIL-induced DISC formation under 
hypoxic conditions (Figure 2C). Consequently, enforcing 
a mitochondria-independent type-I mode of cell death 
should restore TRAIL cytotoxicity in hypoxia. In line 
with this hypothesis, XIAP-deficient HCT116 (HCT116 
XIAP-/-) cells displayed a tremendously reduced TRAIL 
resistance under hypoxic conditions (Figure 5A) compared 
to HCT116 wildtype cells (Figure 1A). Blocking Sp1-
mediated XIAP transcription using mithramycin-A 
(MithA) [25] (Figure 5B) enhanced TRAIL-induced cell 
death in HCT116 cells with a dysfunctional mitochondrial 
cell death pathway due to Bax-deficiency (Figure 5C). 
Moreover, MithA treatment of hypoxic HCT116 (Figures 
5D and 5E), HCT-8 (Figures 5F and 5G) and DLD1 
cells (Figure 5H) restored TRAIL- and CD95L-induced 
cell death. Inhibition of caspases using zVAD-fmk fully 
rescued MithA-treated DLD1 cells under hypoxia from 
TRAIL-induced cell death (Figure 5I) and combinatorial 
treatment with BV6 and TRAIL strongly increased PS 
exposure at the outer leaflet of the plasma membrane 
(Figure 5J). This argued for ongoing apoptosis in a 
mitochondria-independent type-I mode and we therefore 
next investigated the requirement for mitochondria-
derived amplification of the death signal when XIAP 
is blocked. TRAIL-induced cleavage of the caspase-8 
substrate Bid to tBid was equally effective in DLD1 cells 
grown under hypoxic or normoxic conditions (Figure 
6A), which is in line with preserved DISC formation 
(Figure 2C) and caspase-8 activation (Figure 2D). In 
lysates from isolated mitochondria, we also observed no 
oxygen-dependent differences in TRAIL-induced Bid/tBid 
translocation to the mitochondria (Figure 6B), pointing to 
a resistance mechanism downstream of these initial steps 
of the mitochondrial amplification loop. Notably, hypoxia 
reduced the amount of the mitochondrial protein TOM20 
(Figure 6B) and the total cellular content of cytochrome c 
(Figure 6C), which conforms to the previously observed 
hypoxia-induced loss of mitochondrial mass (Figure 
3B). These observations support our hypothesis that 
hypoxia-induced mitophagy and concomitant reduction of 
mitochondria-derived pro-apoptotic molecules is the key 
mechanism for TRAIL-resistance granted during hypoxia. 
Restoring TRAIL-induced apoptosis using XIAP-targeting 
drugs did not depend on mitochondrial amplification 
of the death signal, as robust caspase-3 activation in 
HCT116 Bax-/- cells was observable upon challenge with 
TRAIL+BV6 or TRAIL+MithA even though release 
of mitochondria-derived pro-apoptotic molecules was 
defective (Figure 6D). Likewise, hypoxia-induced 
mitophagy reduced TRAIL-triggered caspase-3 activation 
in HCT116 cells to levels of HCT116 Bax-/- cells. Again, 
BV6 and MithA fully restored TRAIL-induced caspase-3 
activation under hypoxic conditions. In sum, these data 
suggested that XIAP was essential for hypoxia-induced 
TRAIL resistance and targeting this druggable molecule 
rendered mitochondrial amplification of the apoptotic 
stimulus superfluous.
Combinations of TRAIL with SMAC mimetics 
or mithramycin-A are also effective in colorectal 
cancer cells displaying apoptosis resistance 
under ample oxygen
Tumor cells may not depend on hypoxia to develop 
TRAIL resistance, but already exhibit this trait under 
normoxic conditions. Therefore, we questioned whether 
combinatorial treatment with TRAIL plus SMAC mimetics 
or MithA was also efficient in colorectal cancer cells with 
TRAIL resistance under normoxia. In combination with 
the SMAC mimetics BV6 or LCL161, TRAIL robustly 
induced cell death in HT29 (Figures 7A and 7B) and 
SW480 cells (Figures 7D and 7E). Comparable to SMAC 
mimetics, MithA also sensitized HT29 and SW480 
cells to TRAIL-induced apoptosis (Figures 7C and 7F). 
Noteworthy, in the absence of these compounds the 
apoptotic response to TRAIL in both cell lines was at best 
moderate.
Hypoxia reduces efficacy of apoptosis-inducing 
anti-cancer drugs in colorectal cancer cells
We finally investigated whether apoptosis induction 
of anti-cancer drugs such as cis-platin (cisPt) and 
staurosporine (STS) was also impaired under low oxygen 
conditions. Compared to normoxia, we observed reduced 
cytotoxicity of both cisPt and STS in hypoxic DLD1, 
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Figure 5: XIAP is critical for hypoxia-induced TRAIL resistance. A. left panel: HCT116 XIAP-/- cells were grown under 
normoxic (21% O2) and hypoxic (0.5% O2) conditions for 18 h. Following stimulation with the indicated concentrations of TRAIL for 
another 18 h, viability was measured using MTT staining. Values are means ± SEM from three experiments. Right panel: XIAP expression 
in HCT116 wildtype and HCT116 XIAP-/- cells was assessed by Western blotting. Tubulin served as loading control. B. HCT116, HCT-
8 and DLD1 cells were grown as in (A) in the presence and absence of mithramycin-A (HCT-8 and DLD1: 125 nM; HCT116: 10 nM). 
XIAP levels were analyzed by Western blotting, tubulin served as loading control. MithA, mithramycin-A. C–H. HCT116 Bax-/-, HCT116, 
HCT-8 and DLD1 cells were grown as in (A) in the presence and absence of mithramycin-A (HCT116 Bax-/-, HCT-8 and DLD1: 125 nM; 
HCT116: 10 nM) Thereafter, cells were stimulated with the indicated concentrations of TRAIL or CD95L for 18 h and cell viability was 
measured using MTT staining. Values are means ± SEM from three experiments. I. DLD1 cells were grown under hypoxic conditions 
(0.5% O2) for 18 h in the presence of MithA (125 nM, black bars) or MithA and zVAD-fmk (100 μM, white bars). Subsequently, cells were 
treated with the indicated concentrations of TRAIL for 18 h. Cell viability was measured using MTT staining. Values are means ± SEM 
from three experiments. J. DLD1 and HCT-8 cells were grown under hypoxic (0.5% O2) conditions for 18 h in the presence and absence 
of mithramycin-A (125 nM). Subsequently, cells were challenged with the indicated concentrations of TRAIL for 3 h. Translocation of 
phosphatidylserine to the outer leaflet of the plasma membrane was measured using a fluorogenic Annexin V derivate. One representative 
experiment of two performed is shown. PS, phosphatidylserine.
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HCT-8 and HCT116 cells (Figure 8A–8C). Again, BV6 
enhanced the cisPt- and STS-triggered cell death induction 
under low oxygen conditions (Figure 8D).
Summing up, our data demonstrate that colorectal 
cancer cells can acquire TRAIL resistance in a hypoxic 
environment. Mechanistically, this can be traced back to 
hypoxia-induced mitophagy. The later not only disables 
mitochondria-dependent amplification of death receptor-
derived apoptotic signals (and thereby efficiently blocks 
cell death in type-II cells), but also impairs effectivity of 
other apoptosis-inducing anti-cancer drugs. Antagonizing 
anti-apoptotic IAP proteins using SMAC mimetics or 
enforcing a mitochondria-independent type-I mode of 
cell death by targeting XIAP restored sensitivity towards 
apoptosis regardless of oxygen levels and could also be 
exploited therapeutically.
DISCUSSION
Hypoxia regulates numerous genes associated with 
tumor vascularization, invasion, drug resistance and 
metastasis (reviewed in [11]). The effects of hypoxia on 
TRAIL-induced cell death remain to date controversial. 
Initial observations indicated that hypoxia does not impair 
TRAIL-triggered cell death [26], but subsequent reports 
[27–30] and our current study found hypoxia-induced 
TRAIL resistance in a variety of cell lines (Figure 1). 
Notably, hypoxia not only increased resistance to TRAIL- 
but also to CD95L-, cisPt- and STS-induced cell death 
(Figure 1G and 1H, Figure 8). Oxygen deprivation may 
therefore act as a more general protective mechanism 
against apoptosis induction, possibly by disturbing an 
essential death promoting mechanism shared among 
different stimuli. In line with this, our data indicated 
that the hypoxia-induced cell death blockade is located 
downstream of death receptor activation and DISC 
formation, because cell surface expression of TRAIL-R1 
and TRAIL-R2 (Figure 2B), recruitment of DISC 
components (Figure 2C) and caspase-8 activation (Figure 
2D) were preserved under hypoxia. This is essentially in 
accordance with the previously reported intact TRAIL-
induced caspase-8 and Bid cleavage in hypoxic HCT116 
Figure 6: Hypoxia does not affect Bid cleavage and translocation to the mitochondria. A. DLD1 cells were grown under 
normoxic (21% O2) and hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells were challenged with 100 ng/mL TRAIL for the 
indicated periods of time. Processing of Bid into tBid was assessed by Western blotting. Tubulin served as loading control. B. Cells were 
grown as in (A) and challenged with 100 ng/mL TRAIL for the indicated periods of time. Subsequently, cells were harvested, lysed and 
separated into a cytosolic (“C”) and mitochondrial (“M”) fraction. Processing of Bid into tBid and mitochondrial translocation was assessed 
by Western blotting. Detection of TOM20 served as a mitochondrial marker protein to control sufficient fractionation of the lysates. C. 
DLD1 and HCT-8 cells were grown under normoxic (21% O2) or hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells were lysed 
and relative expression levels of cytochrome c were measured using an antibody-based array (see Material and Methods section). Proteins 
were quantified using densitometry and normalized to reference spots. Data shown are means ± SEM from two experiments. AU, arbitrary 
units. D. In the presence and absence of BV6 (6.25 μM) or mithramycin-A (HCT116 Bax-/-: 125 nM, HCT116: 10 nM), HCT116 Bax-/- were 
grown under normoxic (21% O2) conditions and HCT116 cells were grown under hypoxic conditions (0.5% O2) for 18 h. Subsequently, 
cells were challenged with TRAIL (128 ng/mL) for 4 h. Caspase-3 activity was measured using the fluorogenic substrate (DEVD)2-R110. 
One representative experiment of two performed is shown. AU, arbitrary units.
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Bax+/- cells, although that study did not examine death 
receptor expression and DISC formation [31].
The molecular mechanism that impairs TRAIL 
sensitivity in colorectal cancer cells under hypoxia 
is incompletely understood, but a pivotal role for 
mitochondria is emerging. Hypoxic conditions in TRAIL-
treated HCT116 Bax+/- reduced Bax translocation from 
the cytosol to the mitochondria, thereby impairing 
cytochrome c release, subsequent caspase-3 activation and 
apoptosis induction [28, 31]. However, these studies did 
not assess the effects of low oxygen levels on the cellular 
mitochondrial mass. Notably, hypoxia is a potent inducer of 
Figure 7: Combinations of TRAIL with SMAC mimetics or mithramycin-A also overcome TRAIL resistance under 
normoxic conditions. A–F. HT29 and SW480 cells were grown under normoxic (21% O2) and hypoxic (0.5% O2) conditions for 18 
h in the presence and absence of BV6 (6.25 μM) or LCL161 (HT29: 12.5 μM; SW480: 25 μM) or mithramycin-A (125 nM). Thereafter, 
cells were treated with the indicated concentrations of TRAIL for another 18 h. Cell viability was measured using MTT staining. Values are 
means ± SEM from three experiments. MithA, mithramycin-A.
Figure 8: Hypoxia decreases sensitivity of colorectal cancer cells to apoptosis-inducing drugs. A–C. DLD1, HCT-8 and 
HCT116 cells were grown under normoxic (21% O2) and hypoxic (0.5% O2) conditions for 18 h. Subsequently, cells were challenged with 
cis-platin (cisPt, 125 μM) or staurosporine (STS, 5 μM) for another 18 h. Cell viability was measured using MTT staining. Values are means 
± SEM from three experiments. D. DLD1, HCT-8 and HCT116 were grown under normoxic (21% O2) and hypoxic (0.5% O2) conditions 
for 18 h in the presence and absence of BV6 (DLD1: 25 μM; HCT-8 and HCT116: 6.25 μM). Subsequently, cells were challenged with STS 
(5 μM) for another 18 h and cell viability was measured using MTT staining. Values are means ± SEM from three experiments.
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mitophagy [18] and a recent study elegantly demonstrated 
that the mitochondrial outer-membrane protein FUNDC1 
links mitochondria to the autophagic machinery [32]. This 
study also reported reduced cytochrome c levels in cells 
grown under oxygen deprivation. It is therefore tempting 
to speculate that TRAIL resistance could be attributable 
to hypoxia-induced mitophagy rather than inefficient 
mitochondrial translocation of the pore forming Bax/Bak 
complex. Assigning hypoxia-induced TRAIL resistance 
to mitophagy is supported by our data for the following 
reasons: First of all, the decrease of mitochondrial mass 
under low oxygen levels (Figure 3B) was associated 
with enhanced autophagosome formation (Figure 3D). 
Secondly, the autophagy inhibitor 3MA reduced the loss 
of mitochondria under hypoxia (Figure 3E). And finally, 
the autophagy inhibitor 3MA reversed TRAIL resistance 
in hypoxic DLD1, HCT-8 and HCT116 cells (Figure 3F).
Admittedly, blocking autophagy under hypoxia 
using 3MA could also modulate TRAIL susceptibility by 
mitochondria-independent mechanisms. At least under 
normoxia, TRAIL can trigger a protective autophagic 
response that does not involve mitochondria [33, 34]. 
However, hypoxia-induced mitophagy depends on HIF1α 
[18] while TRAIL triggered autophagy does not [33]. The 
HIF1α inhibitor Bay87-2243 [19] restored TRAIL sensitivity 
under hypoxia (Figures 3H and 3I), arguing against 
involvement of TRAIL-triggered protective autophagic 
responses in hypoxia-induced TRAIL resistance.
When apoptosis is blocked, the TRAIL death 
receptors and CD95 can elicit pro-inflammatory signaling 
pathways [35, 36] with tumor promoting activities [7]. In 
vivo, CD95 activation in hypoxic metastasized colorectal 
cancer cells enhanced proliferation and promoted a highly 
invasive phenotype [37]. Consequently, ensuring or 
restoring full-blown cell death induction is a prerequisite 
for therapeutic exploitation of death receptors in cancer 
therapy.
Our study highlights potential new strategies to 
overcome hypoxia-induced TRAIL resistance, either 
by targeting the tumor environment (oxygen levels) or 
by antagonizing cellular adaptions to hypoxia (loss of 
mitochondria). Obviously, oxygen levels determine the 
degree of hypoxia-granted TRAIL resistance (Figure 1J), 
which is reversible upon re-oxygenation (Figure 1I). 
The efficacy of TRAIL-based anti-cancer therapies 
could therefore be boosted by increasing oxygen levels 
in tumors. Respiratory hyperoxia diminished hypoxia in 
the tumor microenvironment in a mouse tumor model 
[38] and additionally enhanced T- and NK-cell mediated 
immunological anti-tumor responses [39]. However, 
systemic hyperoxygenation may be technically challenging 
in the clinical setting. Increasing efficiency of oxygen 
delivery instead by promoting tumor vascularization is 
therefore an interesting alternative. A recent study reported 
that increasing tumor angiogenesis improved drug 
delivery, reduced tumor growth as well as metastasis and 
extended survival [40]. Therefore, combinatorial treatment 
with TRAIL and drugs promoting tumor angiogenesis 
might constitute a reasonable therapeutic approach.
Identification of hypoxia-induced mitophagy as the 
molecular mechanism underlying TRAIL resistance under 
oxygen deprivation allowed us to additionally characterize 
cancer cell intrinsic therapeutic targets. Imitating 
mitochondria-dependent amplification of the TRAIL-
triggered death signal by exogenously adding SMAC 
mimetics (Figure 4C-4H) or enforcing a mitochondria-
independent type-I mode of cell death by targeting XIAP, 
the gatekeeper of the type-II phenotype (Figure 5C-5H) 
[21, 22], boosted TRAIL- and CD95L-induced cell death. 
Both approaches also robustly killed colorectal cancer 
cells that exhibited high-level TRAIL resistance in the 
presence of ample oxygen (Figure 7). Moreover, BV6 
restored cisPt- and STS-induced cell death under hypoxic 
conditions (Figure 8), altogether broadening the clinical 
applicability. SMAC mimetics do not exhibit an exclusive 
specificity for a single IAP protein and target to a varying 
degree cIAP1, cIAP2 and XIAP [41]. XIAP seems to hold 
a crucial role in hypoxia-induced TRAIL resistance, as 
the latter is tremendously reduced in genetically XIAP-
deficient cells and when XIAP transcription is blocked 
(Figure 5). Additionally, XIAP is the most potent caspase 
inhibitor among the IAP proteins [42] and therefore in all 
probability responsible for the TRAIL resistant phenotype 
under hypoxia. However, we can not formally exclude an 
additional role for cIAP1 and cIAP2. Notably, hypoxia 
reduced the total cellular content of XIAP and other anti-
apoptotic molecules (Figure 2A), but apparently not below 
the critical threshold to allow for TRAIL sensitization in the 
absence of mitochondria-derived apoptotic signals (Figure 
1). Although TRAIL death receptors are capable to trigger 
caspase-dependent apoptosis and caspase-independent 
necroptosis [35, 43], zVAD-fmk-mediated rescue (Figure 
4I and 5I) and PS exposure on the outer leaflet of the 
plasma membrane pointed to apoptotic cell death (Figure 
4J and 5J). Killing cancer cells via apoptosis rather than 
necroptosis could therapeutically be desirable as the later 
is capable to initiate a strong inflammatory response [44].
Taken together, we identified hypoxia-induced 
mitophagy as a novel mechanism to regulate TRAIL 
sensitivity in oxygen-deprived colorectal cancer cells 
and characterized cancer cell intrinsic and extrinsic 
approaches for re-sensitization to TRAIL-based anti-
cancer therapy (summarized in Figure 9). Therapeutically, 
we provide experimental evidence that combinatorial 
treatment strategies with TRAIL and SMAC mimetics 
or XIAP-targeting drugs overcome the apoptosis-
hampering conditions imposed by the hypoxic tumor 
microenvironment. Our findings extend previous 
approaches to overcome hypoxia-induced apoptosis 
resistance [29, 30] and also have a broad clinical 




Cell lines, antibodies and reagents
HCT116 and DLD1 cells were purchased from 
the German Collection of Microorganisms and Cell 
Culture (DSMZ, Braunschweig, Germany). HCT-8 cells 
were obtained from Cell Line Service GmbH (CLS, 
Eppelheim, Germany). Cell lines were authenticated 
by STR profiling. HCT116 Bax-/- [45] and HCT116 
XIAP-/- [46] cells were kindly provided by Bert 
Vogelstein (Johns Hopkins University, Baltimore, 
MA, USA) and Philipp Jost (III. Medizinische 
Klinik, Technische Universität München, Germany), 
respectively. Cells were cultured in RPMI 1640 
medium (PAN Biotech, Aidenbach, Germany) 
supplemented with 10% [v/v] fetal calf serum (Sigma, 
Steinheim, Germany). Oxygen levels were modulated 
using a Whitley H35 Hypoxystation (Don Whitley 
Scientific, Shipley, UK). Antibodies specific for 
FADD, caspase-8, Bax and XIAP were purchased 
from Cell Signaling Technology (Beverly, MA, USA). 
Anti-TRAIL-R1, anti-TRAIL-R2, anti-TRAIL-R3 
and anti-TRAIL-R4 antibodies were from ProSci 
(Poway, CA, USA), anti-HIF1α was from Cayman 
Chemical (Ann Arbor, MI, USA) and anti-tubulin from 
Dunnlab (Asbach, Germany). BV6, LCL161, Bay87-
2243, staurosporine (STS), cis-platin (cisPt) and 
3-methyladenine (3MA) were obtained from Selleck 
Chemicals (Houston, TX, USA). Mithramycin-A 
was from AppliChem (Darmstadt, Germany), zVAD-
fmk from Bachem (Heidelberg, Germany) and MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide) from Biomol (Hamburg, Germany). Human 
recombinant TRAIL was purchased from Apronex 
(Jesenice u Prahy, Czech Republic) and CD95L was 
from Adipogen (Liestal, Switzerland). Fc-FLAG-
scTRAIL was generated by in-frame insertion of 
FLAG-scTRAIL [47] into a pCR3 variant encoding 
the IgG1 Fc domain and a linker (kind gift from P. 
Schneider, Department of Biochemistry, University 
of Lausanne). Recombinant Fc-FLAG-TRAIL was 
produced in HEK293 cells as previously described for 
TL1A [48].
Figure 9: Molecular mechanism of hypoxia-induced TRAIL resistance in colorectal cancer cells. Under normoxic conditions, 
TRAIL-R1/-R2 activation triggers DISC assembly with subsequent caspase-8 activation. Mitochondria amplify the death signal via the 
release of pro-apoptotic factors such as cytochrome c and SMAC, which boost caspase-3 activation by initiating apoptosome formation and 
antagonizing XIAP, respectively. Under hypoxic conditions, mitophagy sequesters mitochondria-derived pro-apoptotic molecules, thereby 
blocking efficient apoptosis induction. Therapeutically, hypoxia-induced TRAIL resistance can be overcome by (1) increasing local oxygen 
levels (e.g. systemic hyperoxia or promoting angiogenesis), (2) inhibition of hypoxia-induced mitophagy (e.g. Bay87-2243 targeting HIF1α 
or 3MA blocking autophagosome formation) or (3) targeting XIAP (e.g. SMAC mimetics or blocking XIAP transcription using MithA).
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Western blot analysis
Western blot analysis were performed essentially 
as described previously [7]. Briefly, cells were harvested, 
spun down, and dissolved in 4x Laemmli sample buffer (8% 
[w/v] SDS, 0.1 M dithiothreitol, 40% [v/v] glycerol, 0.2 
M Tris, pH 8.0) supplemented with phosphatase inhibitor 
cocktails-I and -II (Sigma). Samples were sonificated, 
subsequently boiled (96°C, 5 min). Proteins were separated 
by SDS-PAGE and transferred to PVDF membranes. 
Incubation in TBS containing 0.1% (v/v) Tween 20 and 
5% (w/v) dry milk blocked non-specific binding sites. 
Membranes were incubated with primary antibodies of 
the specificity of interest. Antigen-antibody complexes 
were visualized using horseradish peroxidase-conjugated 
secondary antibodies (Dako, Hamburg, Germany) and ECL 
technology (Pierce, Rockford, IL, USA). Mitochondria 
were isolated using the “Mitochondria Isolation Kit for 
Cultured Cells” (ThermoFisher Scientific, Waltham, MA, 
USA) following manufacturer’s instructions.
Coimmunoprecipitation
Immunoprecipitation of Fc-FLAG-scTRAIL was 
essentially performed as described previously for CD95L 
[7]. In brief, four confluent 150 cm2 tissue culture dishes 
per condition were stimulated with 1 μg/mL Fc-FLAG-
scTRAIL for 90 min at 37°C, washed in ice-cold TBS, 
transferred in 2 mL lysis buffer (50 mM Tris–HCl, pH 
7.5, 150 mM NaCl, 0.5% [v/v] NP40) supplemented with 
complete protease inhibitor cocktail (Roche, Mannheim, 
Germany), and incubated for 60 min on ice. Lysates 
were cleared by centrifugation (2 × 20 min, 14.000 g) 
and TRAIL-R1/-R2 complexes were precipitated using 
protein G agarose (Roche, 40 μL of a 50% [v/v] slurry) 
at 4°C overnight. Lysates from unstimulated cells 
supplemented with 50 ng/mL of Fc-FLAG-scTRAIL 
before adding protein G agarose served as negative 
control. After washing three times in TBS, agarose-
bound proteins were eluted by incubation at 95°C for 10 
min in 2x Laemmli sample buffer.
Cell viability assay
Cells were seeded in 96-well plates (2×104 per 
well) and grown in the presence of the indicated oxygen 
levels for 18 h. Subsequently, cells were stimulated 
with the indicated concentrations of the ligands in 
triplicates. Cell viability was determined 18 h after 
stimulation using 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) or crystal violet 
staining.
Flow cytometry
Cells were grown under normoxic (21% O2) or 
hypoxic (0.5% O2) conditions for 18 h, harvested, and 
incubated for 30 min on ice with PE-conjugated antibodies 
specific for the indicated TRAIL-receptors (Diaclone SAS, 
Besancon, France) or an appropriate isotype control (R&D 
Systems). Analyses were performed using FACSCanto 
II (BD Biosciences, Heidelberg, Germany) following 
standard procedures.
Caspase activity assay and phosphatidylserine 
measurements
3×104 cells per well were seeded in black 96-
well plates (clear bottom) and grown under normoxic 
(21% O2) or hypoxic (0.5% O2) conditions for 18 h. 
Subsequently, cells were challenged with the indicated 
concentrations of TRAIL for 3 h (phosphatidylserine 
measurements), 4 h (caspase-8 measurements) or 
5 h (caspase-3 measurements). Translocation of 
phosphatidylserine to the outer leaflet of the plasma 
membrane was determined using a fluorogenic Annexin 
V derivate (Phosphatidylserine apoptosis assay, AAT 
Bioquest, Sunnyvale, CA, USA). Caspase activity 
was determined using the fluorogenic substrates 
(DEVD)2-R110 (Caspase-3 activity kit, AAT Bioquest) 
or (Ac-IETD)2-R110 (Caspase-8 activity kit, AAT 
Bioquest) according to the manufacturer’s instructions. 
Light emission was quantified using a Victor3 multilabel 
reader (Perkin Elmer, Waltham, MA, USA). All groups 
were analyzed in triplicates.
Fluorescence-based measurements of 
mitochondrial mass
DLD1 cells were seeded in black 96-well plates 
(3×104 cells/well) with clear bottom and grown under 
normoxic or hypoxic conditions for 18 h. Before staining, 
cells were washed once with 37°C warm Hank’s buffered 
salt solution (HBSS, Sigma) and incubated with 200 
nM MitoTracker Green FM (ThermoFisher Scientific) 
for 45 min at 37°C protected from light. Subsequently, 
staining solution was removed by aspiration, cells were 
again washed in HBSS and fluorescence intensity was 
measured using a Victor3 multilabel reader (Perkin 
Elmer, Waltham, MA, USA). All groups were analyzed 
in triplicates.
Fluorescence-based autophagy assay
Autophagosome formation was measured using 
the “Cell Meter™ Autophagy Fluorescence Imaging 
Kit” (AAT Bioquest) according to manufacturer’s 
instructions. In brief, 3×104 cells per well cells were 
seeded in black 96-well plates and incubated for 18 h 
under normoxic or hypoxic conditions. Autophagosomes 
were stained after media removal by incubation for 1 h 
in PhagyGreen™ staining solution at 37°C protected 
from light. Subsequently, cells were washed three times 
and fluorescence intensity was measured using a Victor3 
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multilabel reader (Perkin Elmer). All groups were 
analyzed in triplicates.
Measurement of cytosolic Ca2+ levels
Cytosolic Ca2+ levels were measured using the 
“Fluo-4 Direct Calcium Assay” (ThermoFisher Scientific). 
Cells were seeded in black 96-well plates (3×104 per 
well) and incubated for 18 h under normoxic or hypoxic 
conditions. Subsequently, cells were challenged with 
TRAIL (256 ng/mL) for the indicated periods of time 
followed by direct addition of the Fluo-4-containing 
staining solution into the culture media. Fluorescence 
intensity was measured after 1 h incubation (37°C, 
protected from light) using a Victor3 multilabel reader 
(Perkin Elmer).
Proteomic profiling
Oxygen-dependent changes in the relative 
expression of pro- and anti-apoptotic proteins were 
analyzed in DLD1 cells grown under normoxic (21% 
O2) or hypoxic (0.5% O2) conditions for 18 h using the 
“Human Apoptosis Antibody Array Kit” (R&D Systems, 
Wiesbaden, Germany) according to manufacturer’s 
instructions. Intensity of the protein spots were quantified 
by densitometry using the open source software ImageJ 
1.47v (Wayne Rasband; National Institutes of Health, 
Bethesda, MD, USA) and normalized to reference spots 
included in each panel.
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